BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15953008)

  • 1. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease.
    Athale UH; Siciliano SA; Crowther M; Barr RD; Chan AK
    Br J Haematol; 2005 Jun; 129(6):803-10. PubMed ID: 15953008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols.
    Desai SJ; Barr RD; Andrew M; deVeber LL; Pai MK
    CMAJ; 1989 Oct; 141(7):693-7. PubMed ID: 2790605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
    Barry E; DeAngelo DJ; Neuberg D; Stevenson K; Loh ML; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin M; Cohen HJ; Sallan SE; Silverman LB
    J Clin Oncol; 2007 Mar; 25(7):813-9. PubMed ID: 17327603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
    Meister B; Kropshofer G; Klein-Franke A; Strasak AM; Hager J; Streif W
    Pediatr Blood Cancer; 2008 Feb; 50(2):298-303. PubMed ID: 17443678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
    Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
    J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulation and fibrinolysis in children with acute lymphoblastic leukaemia treated according to the COALL-05-92-protocol.
    Kirschke R; Nürnberger W; Eckhof-Donovan S; Nürnberger I; Göbel U
    Klin Padiatr; 1998; 210(4):285-90. PubMed ID: 9743967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).
    Mauz-Körholz C; Junker R; Göbel U; Nowak-Göttl U
    Thromb Haemost; 2000 Jun; 83(6):840-3. PubMed ID: 10896235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer.
    Athale U; Siciliano S; Thabane L; Pai N; Cox S; Lathia A; Khan A; Armstrong A; Chan AK
    Pediatr Blood Cancer; 2008 Dec; 51(6):792-7. PubMed ID: 18798556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.
    Goldberg JM; Silverman LB; Levy DE; Dalton VK; Gelber RD; Lehmann L; Cohen HJ; Sallan SE; Asselin BL
    J Clin Oncol; 2003 Oct; 21(19):3616-22. PubMed ID: 14512392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a protocol for a prospective, observational, cohort study.
    Athale UH; Laverdiere C; Nayiager T; Delva YL; Foster G; Thabane L; Chan AK
    BMC Cancer; 2017 May; 17(1):313. PubMed ID: 28472942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment.
    Mitchell LG; Sutor AH; Andrew M
    Semin Thromb Hemost; 1995; 21(4):390-401. PubMed ID: 8747702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.
    Barry EV; Vrooman LM; Dahlberg SE; Neuberg DS; Asselin BL; Athale UH; Clavell LA; Larsen EC; Moghrabi A; Samson Y; Schorin MA; Cohen HJ; Lipshultz SE; Sallan SE; Silverman LB
    J Clin Oncol; 2008 Mar; 26(7):1106-11. PubMed ID: 18309945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
    Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
    J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia.
    Hurwitz CA; Silverman LB; Schorin MA; Clavell LA; Dalton VK; Glick KM; Gelber RD; Sallan SE
    Cancer; 2000 Apr; 88(8):1964-9. PubMed ID: 10760775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
    Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
    Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01.
    Waber DP; Turek J; Catania L; Stevenson K; Robaey P; Romero I; Adams H; Alyman C; Jandet-Brunet C; Neuberg DS; Sallan SE; Silverman LB
    J Clin Oncol; 2007 Nov; 25(31):4914-21. PubMed ID: 17971588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity.
    Waber DP; Silverman LB; Catania L; Mautz W; Rue M; Gelber RD; Levy DE; Goldwasser MA; Adams H; Dufresne A; Metzger V; Romero I; Tarbell NJ; Dalton VK; Sallan SE
    J Clin Oncol; 2004 Jul; 22(13):2701-7. PubMed ID: 15226337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.
    Ribera JM; Oriol A; Sanz MA; Tormo M; Fernández-Abellán P; del Potro E; Abella E; Bueno J; Parody R; Bastida P; Grande C; Heras I; Bethencourt C; Feliu E; Ortega JJ
    J Clin Oncol; 2008 Apr; 26(11):1843-9. PubMed ID: 18398150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone and mineral abnormalities in childhood acute lymphoblastic leukemia: influence of disease, drugs and nutrition.
    Atkinson SA; Halton JM; Bradley C; Wu B; Barr RD
    Int J Cancer Suppl; 1998; 11():35-9. PubMed ID: 9876475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.